The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients.

IF 1.5 4区医学 Q4 GENETICS & HEREDITY

Psychiatric Genetics Pub Date : 2021-06-01 DOI:10.1097/YPG.0000000000000279

Patrick S Thomas, Ellen M Nielsen, Catherine J Spellicy, Mark J Harding, An Ye, Michelle Patriquin, Sara C Hamon, Thomas R Kosten, David A Nielsen

{"title":"The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients.","authors":"Patrick S Thomas, Ellen M Nielsen, Catherine J Spellicy, Mark J Harding, An Ye, Michelle Patriquin, Sara C Hamon, Thomas R Kosten, David A Nielsen","doi":"10.1097/YPG.0000000000000279","DOIUrl":null,"url":null,"abstract":"Objective: Prior research demonstrated that the δ-opioid receptor (OPRD1) rs678849 variant influences opioid use in African Americans treated with methadone. We examined whether this variant moderated cocaine and opioid use in our clinical cohort of methadone and disulfiram treated recipients.Methods: Cocaine and opioid codependent patients were stabilized for 2 weeks on methadone and subsequently randomized into groups treated with either methadone + placebo (n = 37) or methadone + disulfiram (250 mg/day; n = 33) for 12 weeks.Results: A drop in cocaine-positive urine was found in the OPRD1 CC genotype group compared to T-allele carrier patients treated with methadone + disulfiram (P < 0.0001), but not in the methadone + placebo group. No difference in opioid-positive urines was found among each genotype group in either treatment group.Conclusion: These findings suggested that rs678849 genotype may predict treatment response of disulfiram for cocaine use in patients with co-occurring opioid and cocaine dependence.","PeriodicalId":20734,"journal":{"name":"Psychiatric Genetics","volume":"31 3","pages":"88-94"},"PeriodicalIF":1.5000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8108700/pdf/nihms-1682743.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatric Genetics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/YPG.0000000000000279","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 2

Abstract

Objective: Prior research demonstrated that the δ-opioid receptor (OPRD1) rs678849 variant influences opioid use in African Americans treated with methadone. We examined whether this variant moderated cocaine and opioid use in our clinical cohort of methadone and disulfiram treated recipients.

Methods: Cocaine and opioid codependent patients were stabilized for 2 weeks on methadone and subsequently randomized into groups treated with either methadone + placebo (n = 37) or methadone + disulfiram (250 mg/day; n = 33) for 12 weeks.

Results: A drop in cocaine-positive urine was found in the OPRD1 CC genotype group compared to T-allele carrier patients treated with methadone + disulfiram (P < 0.0001), but not in the methadone + placebo group. No difference in opioid-positive urines was found among each genotype group in either treatment group.

Conclusion: These findings suggested that rs678849 genotype may predict treatment response of disulfiram for cocaine use in patients with co-occurring opioid and cocaine dependence.

查看原文本刊更多论文

OPRD1 rs678849变异影响美沙酮维持患者可卡因依赖双硫仑治疗的结果。

目的:先前的研究表明δ-阿片样物质受体(OPRD1) rs678849变异影响美沙酮治疗的非裔美国人阿片样物质的使用。我们研究了在美沙酮和双硫仑治疗接受者的临床队列中，这种变异是否减缓了可卡因和阿片类药物的使用。方法:可卡因和阿片类药物相互依赖的患者在美沙酮治疗2周后稳定，随后随机分为美沙酮+安慰剂组(n = 37)或美沙酮+双硫仑组(250 mg/天;N = 33)，持续12周。结果:与t等位基因携带者美沙酮+双硫仑治疗的患者相比，OPRD1 CC基因型组可卡因阳性尿明显下降(P)。结论:这些发现提示rs678849基因型可能预测双硫仑治疗同时发生阿片类药物和可卡因依赖的患者可卡因使用的治疗反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Psychiatric Genetics 医学-神经科学

CiteScore

2.30

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： The journal aims to publish papers which bring together clinical observations, psychological and behavioural abnormalities and genetic data. All papers are fully refereed. Psychiatric Genetics is also a forum for reporting new approaches to genetic research in psychiatry and neurology utilizing novel techniques or methodologies. Psychiatric Genetics publishes original Research Reports dealing with inherited factors involved in psychiatric and neurological disorders. This encompasses gene localization and chromosome markers, changes in neuronal gene expression related to psychiatric disease, linkage genetics analyses, family, twin and adoption studies, and genetically based animal models of neuropsychiatric disease. The journal covers areas such as molecular neurobiology and molecular genetics relevant to mental illness. Reviews of the literature and Commentaries in areas of current interest will be considered for publication. Reviews and Commentaries in areas outside psychiatric genetics, but of interest and importance to Psychiatric Genetics, will also be considered. Psychiatric Genetics also publishes Book Reviews, Brief Reports and Conference Reports.